Skip to main content
. Author manuscript; available in PMC: 2015 Mar 9.
Published in final edited form as: J Immunother. 2015 Jan;38(1):24–36. doi: 10.1097/CJI.0000000000000059

Figure 1. Protocol schema.

Figure 1

Bortezomib (Bor) was given (1.0mg/m2, day −9, −6, −2) to enhance NK cell therapy by down-regulating expression of HLA Class I,15 and up regulating TRAIL receptor on the myeloma cell surface. 16,46,47 Subjects 1, 2, 3, 5 and 8 also received immunosuppression with cyclophosphamide (Cy) 60 mg/kg IV on day −7, dexamethasone (Dex) 40 mg PO days −6 to −3, and fludarabine (Flu) 25 mg/m2 IV days −6 to −2 to reduce T regs and to prevent early rejection of infused NK cells. One administration of 2×107–1×108/kg of NK cells was given on day 0 and followed by 13 doses of daily IL2 (3×106 U, SC) to support the persistence and activity of NK cells in vivo.